Shire PLC



    Today's change

    102.00 / +2.16%

    1 year change


    As of Jan 23 2015 17:11 GMT. Data delayed by at least 15 minutes.

Search for Shire PLC and
  1. January 12, 2015

    Shire: details matter

    Announcing its $5.2bn purchase of NPS Pharma, Shire said it “expects that the transaction will deliver return on invested...

  2. January 12, 2015

    NPS prospects dependent on drug approval

    Shire’s $5.2bn acquisition of NPS Pharmaceuticals on Sunday was the latest example of a larger drugmaker making a big gamble...

  1. January 12, 2015

    Fresh round of M&A sweeps pharma sector

    Another round of mergers and acquisitions is sweeping the pharmaceuticals sector, in a sign that last year’s boom in...

  2. FT Alphaville

    January 12, 2015


    A show of unity in Paris, an AirAsia black box and Apple’s secret door More than 3.7m marched in Paris and across France in...

  3. FT Alphaville

    January 12, 2015

    FirstFT (the new 6am cut)

    Read the email in full below or sign up to receive it here. More than 3.7m marched in Paris and across France in a display...

  4. January 11, 2015

    Shire in $5.2bn deal for US biotech NPS

    Shire, Britain’s third-largest drugmaker by market value, has made its biggest ever acquisition with a $5.2bn deal for US...

  5. January 7, 2015

    Pharma takeover battles boost FTSE 100 performance

    Two companies at the centre of takeover battles had the biggest positive impact on the performance of the FTSE 100 last...

  6. January 1, 2015

    Corporate chiefs’ predictions for 2015

    What do corporate chiefs expect in 2015? FT journalists gather predictions, hopes and fears from the UK and elsewhere....

  7. December 22, 2014

    Takeover volumes move to highest post-crisis levels

    Corporate takeover deals surged to their highest levels since the financial crisis this year, with merger and acquisition...

  8. December 14, 2014

    Bank traders lose big on AbbVie-Shire bets

    City of London trading desks at several big investment banks lost money after the collapse of AbbVie’s $54bn takeover offer...

  9. December 11, 2014

    Investors warm to Shire’s independence

    Two months after a bid from AbbVie collapsed, investors have been feeling more comfortable with the idea of Shire staying...

  10. December 8, 2014

    PwC sold ‘tax avoidance on industrial scale’

    MPs accused a firm of accountants of “selling tax avoidance on an industrial scale” on Monday after a tense parliamentary...

  11. November 10, 2014

    Bets gone awry push John Paulson event-driven fund to loss

    John Paulson’s $3bn event-driven hedge fund swung to a 14 per cent loss last month as the investor known for making billions...

  12. November 4, 2014

    Ackman gains ground in fight to force Allergan to sell to Valeant

    Bill Ackman chalked up a big victory in his battle to force Allergan, the maker of blockbuster wrinkle treatment Botox, to...

  13. October 31, 2014

    Boardroom trades November 1

    Matthew Emmens sold shares in Shire as he stepped down as chairman of the pharmaceutical group in March. The shares went...

  14. October 26, 2014

    Right financial officer for the right era

    A new man for a new era. That seems to be the mantra of a series of British companies that are looking to replace their...

  15. October 24, 2014

    Shire and AstraZeneca show standalone strength

    Britain’s number two and three drugmakers burnished their strength as independent companies on Friday when Shire reported...

  16. October 22, 2014

    AbbVie and HP: corporate writing stinks and the CEO is to blame

    AbbVie, the US drugs company, no longer wants to take over Shire, a UK counterpart. Richard Gonzalez, AbbVie’s chief...

  17. October 21, 2014

    Shire interim CFO jumps ship for Severn Trent

    Shire has lost its interim chief financial officer to Severn Trent, increasing the upheaval surrounding the UK-listed...

  18. October 20, 2014

    AbbVie hits at Treasury as Shire deal dies

    The head of AbbVie, which last week dropped its support for a $55bn takeover of UK drugmaker Shire, slammed the US Treasury...

  19. October 19, 2014

    Long-term reforms of US tax system required to stop ‘deserters’

    Spare a thought for the poor US multinational. It has had a horrible time lately and been called lots of beastly names. Back...

  20. October 19, 2014

    M&A deal failure at highest since 2008

    The value of deals that fail to complete has reached its highest level since 2008, in the latest sign that the best year for...

  21. October 17, 2014

    Pfizer’s AstraZeneca pursuit knocked by Shire deal collapse

    The chances of Pfizer reviving its pursuit of AstraZeneca have been greatly diminished after the collapse of AbbVie’s £32bn...

  22. October 16, 2014

    Tax changes roil inversion deals

    The sudden collapse of AbbVie’s proposed $54bn takeover of rival drugmaker Shire does not necessarily signal that the Obama...

  23. October 16, 2014

    When shares fall off a cliff, deal-doers are left running on thin air

    All battle plans evaporate on contact with the enemy, which for City deal-doers is a slumping equities market. A 10 per cent...

  24. October 16, 2014

    AbbVie drops proposed $54bn Shire deal

    AbbVie, the US pharmaceuticals group, blamed a White House crackdown on tax inversions as it dropped its proposed $54bn...

  25. October 16, 2014

    FTSE 100 lower as rebound fails to hold

    The FTSE 100 was sharply lower by late morning on Thursday, as an attempted rebound failed to last amid stubborn worries...

  26. October 15, 2014

    AbbVie drops £32bn bombshell on Shire

    Only two weeks ago AbbVie’s chief executive, Richard Gonzales, sent a letter to Shire employees saying he was “more...

  27. October 15, 2014

    AbbVie and Shire: the tail of the tax tale

    One of the more lamentable products launched by the insurance industry is wedding insurance, offering protection if the big...

  28. October 15, 2014

    Shire deal threat flays hedge funds

    Some of the world’s largest hedge funds were left nursing heavy losses on Wednesday as US pharmaceuticals group AbbVie left...

  29. October 15, 2014

    Inversions should not (hop) scotch healthy trend for tax competition

    We come not to bury tax inversions but to praise them. The news that US drugs group AbbVie of the US may back out of its...

  30. FT Alphaville

    October 15, 2014

    Shire-AbbVie: arbitrage against the machine

    Cold feet or negotiation tactic? No one knows. And the people prepared to guess were 25 per cent wrong about Shire’s price...

  31. October 15, 2014

    Pharma stocks slide on Shire deal doubts

    News that Abbvie’s £32bn deal to acquire Shire is in danger of failing to complete had deep repercussions on the FTSE 100 on...

  32. October 15, 2014

    CSR valued at £1.56bn after Qualcomm agrees to buy it

    Qualcomm has agreed to buy CSR, in a deal that values the equity of the UK chipmaker at £1.56bn. The recommended all-cash...

  33. October 15, 2014

    AbbVie reconsiders $54bn Shire deal

    AbbVie, the US pharmaceutical company, has said it is reconsidering its $54bn takeover of UK drugmaker Shire, putting it on...

  34. October 3, 2014

    Shire gains on AbbVie takeover hopes

    Drugmaker Shire surged to a record high on Friday as optimism strengthened that its $54bn takeover by AbbVie will complete....

  35. October 3, 2014

    Salix pulls deal amid US tax crackdown

    A $2.7bn deal between drugmakers Salix of the US and Cosmo of Italy has become the first victim of President Barack Obama’s...

  36. September 23, 2014

    Curbs on tax inversions fail to convince

    Dissections of a White House plan to curb tax-driven mergers gave way on Tuesday to a realisation that the most significant...

  37. September 23, 2014

    US Treasury hopes to stand logic of tax inversion deals on head

    Taxes may be one of the only two certainties, but tax benefits are very uncertain – as the US Treasury has just...

  38. September 19, 2014

    Highlights from this week’s Investors Chronicle

    Buy: Shire (SHP) Shire is re-establishing itself as a market-leader in rare diseases and we have faith the company will...

Search for Shire PLC and


Videos from FT.com that closely match this topic

  1. Lex on why tax inversions are losing their appeal...
    October 15, 2014

    Lex on why tax inversions are losing their appeal